Key facts
- It has raised $28.0M; the latest was Early Stage VC ($28.0M) in Sep 2025.
- Notable investors include Shenzhen Capital Group, Green Pine Capital Partners, Shenzhen Nanshan Strategic Emerging Industry Investment, Zhuhai Gree Financial Investment, Chongging Fenshare Holding — 12 tracked in total.
- Status: Privately Held (backing).
Investors
12+- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Rui Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Rui Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rui Therapeutics
Developer of universal cell therapy drugs, focused on advancing CAR-NK, UCAR-T, and CAR-γδT technologies for unmet clinical needs. The company specailises in proprietary cell drug platforms, viral delivery systems, CAR structure designs, and cryopreservation techniques, thereby targeting autoimmune diseases, inflammatory conditions, fibrosis, and anti-ageing applications through first-in-class therapeutic innovations.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- ruitherapeutics.com/
- Ownership
- Privately Held (backing)
Rui Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rui Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rui Therapeutics in its N-PORT filings yet. We sweep new filings monthly.